Dehydrovomifoliol is a AKT/mTOR dual inhibitor. Dehydrovomifoliol reduces lipid accumulation and lipogenesis by inhibiting the AKT/mTOR signaling pathway. Dehydrovomifoliol is used in nonalcoholic fatty liver disease research (NAFLD) .
Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > Akt | Products > Signaling Pathways > mTOR
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.